Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-12 12:18 pm Purchase | 2026-03-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | STATE STREET CORPORATION STT | 3,015,562 5.100% | 1,787,466 (+145.55%) | Filing History |
| 2026-04-29 4:08 pm Sale | 2026-03-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | BlackRock Portfolio Management LLC | 2,508,488 4.200% | -743,075 (-22.85%) | Filing History |
| 2026-03-27 1:55 pm Sale | 2026-03-13 | 13G | VANDA PHARMACEUTICALS INC VNDA | VANGUARD GROUP INC | 0 0.000% | -3,456,087 (Position Closed) | Filing History |
| 2026-01-21 12:26 pm Sale | 2025-12-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | BlackRock Portfolio Management LLC | 3,251,563 5.500% | -1,227,523 (-27.41%) | Filing History |
| 2026-01-09 4:23 pm Sale | 2025-12-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | Integrated Core Strategies (US) LLC | 1,679,013 2.800% | -1,441,326 (-46.19%) | Filing History |
| 2025-07-01 4:31 pm Purchase | 2025-06-27 | 13G | VANDA PHARMACEUTICALS INC VNDA | Integrated Core Strategies (US) LLC | 3,120,339 5.300% | 3,120,339 (New Position) | Filing History |
| 2025-04-15 5:04 pm Purchase | 2025-03-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | BlackRock Portfolio Management LLC | 4,479,086 7.700% | 4,479,086 (New Position) | Filing History |
| 2025-02-07 1:40 pm Sale | 2025-01-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | BlackRock, Inc. BLK | 4,699,280 8.100% | -4,404,924 (-48.38%) | Filing History |
| 2025-02-05 1:23 pm Purchase | 2024-12-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | BlackRock, Inc. BLK | 9,104,204 15.600% | 757,837 (+9.08%) | Filing History |
| 2024-02-13 5:16 pm Sale | 2023-12-29 | 13G | VANDA PHARMACEUTICALS INC VNDA | VANGUARD GROUP INC | 3,456,087 6.010% | -536,079 (-13.43%) | Filing History |
| 2024-02-13 10:53 am Purchase | 2023-12-29 | 13G | VANDA PHARMACEUTICALS INC VNDA | Renaissance Technologies LLC | 3,681,125 6.400% | 791,700 (+27.40%) | Filing History |
| 2024-02-09 09:59 am Sale | 2024-02-14 | 13G | VANDA PHARMACEUTICALS INC VNDA | DIMENSIONAL FUND ADVISORS LP | 1,967,985 3.400% | -885,847 (-31.04%) | Filing History |
| 2024-01-23 11:52 am Purchase | 2023-12-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | BlackRock, Inc. BLK | 8,346,367 14.500% | 1,587,250 (+23.48%) | Filing History |
| 2024-01-22 11:26 am Sale | 2023-12-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | STATE STREET CORPORATION STT | 1,228,096 2.130% | -2,499,702 (-67.06%) | Filing History |
| 2023-10-06 2:34 pm Sale | 2023-09-30 | 13G | VANDA PHARMACEUTICALS INC VNDA | BlackRock, Inc. BLK | 6,759,117 11.800% | -3,567,497 (-34.55%) | Filing History |
| 2023-02-14 4:23 pm Sale | 2022-12-31 | 13G | VANDA PHARMACEUTICALS INC VNDA | Palo Alto Investors LP | 1,087,064 1.420% | -1,747,180 (-61.65%) | Filing History |
| 2023-02-14 1:34 pm Sale | 2022-12-30 | 13G | VANDA PHARMACEUTICALS INC VNDA | MACQUARIE GROUP LTD | 1,323,547 2.340% | -1,589,924 (-54.57%) | Filing History |
| 2023-02-13 11:33 am Sale | 2022-12-30 | 13G | VANDA PHARMACEUTICALS INC VNDA | Renaissance Technologies LLC | 2,889,425 5.090% | -322,789 (-10.05%) | Filing History |
| 2023-02-10 2:42 pm Purchase | 2023-02-14 | 13G | VANDA PHARMACEUTICALS INC VNDA | DIMENSIONAL FUND ADVISORS LP | 2,853,832 5.000% | 2,853,832 (New Position) | Filing History |
| 2023-02-09 11:35 am Purchase | 2022-12-30 | 13G | VANDA PHARMACEUTICALS INC VNDA | VANGUARD GROUP INC | 3,992,166 7.050% | 115,482 (+2.98%) | Filing History |